Division of Pediatric Gastroenterology, Hepatology and Nutrition, Columbia University Medical Center, New York, New York.
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Columbia University Medical Center, New York, New York.
Gastroenterology. 2020 May;158(7):1967-1983.e1. doi: 10.1053/j.gastro.2020.01.048. Epub 2020 Mar 20.
Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence in concert with the global epidemic of obesity and is being diagnosed at increasingly younger ages. The unique histologic features and early presentation of disease in pediatrics suggest that children and adults may differ with regard to etiopathogenesis, with children displaying a greater vulnerability to genetic and environmental factors. Of significant relevance to pediatrics, in utero and perinatal stressors may alter the lifelong health trajectory of a child, increasing the risk of NAFLD and other cardiometabolic diseases. The development and progression of disease in childhood is likely to carry increased risk of long-term morbidity. Novel biomarkers and therapeutic agents are needed to avoid the otherwise inevitable health and societal consequences of this rapidly expanding pediatric population.
非酒精性脂肪性肝病(NAFLD)随着肥胖症的全球流行而发病率不断增加,且发病年龄越来越年轻化。儿科疾病独特的组织学特征和早期表现表明,儿童和成人在发病机制上可能存在差异,儿童对遗传和环境因素的易感性更大。值得儿科关注的是,宫内和围产期压力可能会改变儿童的终身健康轨迹,增加非酒精性脂肪性肝病和其他心血管代谢疾病的风险。儿童期疾病的发生和发展可能会增加长期发病的风险。需要新的生物标志物和治疗药物来避免这一快速增长的儿科人群不可避免的健康和社会后果。